TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04715373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LISA
Description: LISA administered in the DR after initial resuscitation or in the NICU after stepwise escalation of CPAP based on FiO2 ≥0.3. While maintaining infant on CPAP with binasal prongs/small nasal mask, a thin catheter (Hobart method) is inserted below the vocal cord using direct laryngoscopy. Poractant alfa (200mg/kg) is administered slowly over 2-3 minutes. Catheter is then withdrawn and infant is maintained on CPAP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LISA
Description: LISA administered in the DR after initial resuscitation or in the NICU after stepwise escalation of CPAP based on FiO2 ≥0.3. While maintaining infant on CPAP with binasal prongs/small nasal mask, a thin catheter (Hobart method) is inserted below the vocal cord using direct laryngoscopy. Poractant alfa (200mg/kg) is administered slowly over 2-3 minutes. Catheter is then withdrawn and infant is maintained on CPAP
Study: NCT06566261

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABA-101
Description: ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABA-101
Description: ABA-101 is a TCR engineered, autologous regulatory T cell (Treg) therapy
Study: NCT04975997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.
Study: NCT06276647

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOME
Description: The study intervention consists of a patient education pamphlet and partner sheet (physically and virtually accessible) that will educate and prepare post-partum patients. The patient navigator will explain this pamphlet at postpartum discharge, then will follow-up with the patients up to 30 days in the postpartum period.
Study: NCT06153251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986453
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study: NCT05388045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Reported Outcome Measure
Description: A Recovery Patient-Reported Outcome Measure (PROM, 19 items and 2 questions for each item, collected via online survey) will be completed by eligible patients at baseline and again at months 3 and 6. The initial Recovery PROM will be shared with the clinician, at the visit most closely scheduled following the baseline visit, for review and discussion with the patient. At the 3- and 6-month visits, the clinician will be asked to re-review and compare the earlier Recovery PROM(s) as well as the current Recovery PROM. The clinician is encouraged to use the PROM results during interim clinical visits with the patient. Efforts will be made to contemporaneously track how often the PROM is discussed in clinical sessions conducted during the 6 months.
Study: NCT05896254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAR001
Description: Subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study: NCT06012240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Tablets
Study: NCT05695339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: An injection of 1-2 ml bupivacaine 0.5% will be placed around the affected branch of the neuroma (aiming at its proximal end) and dorsal adjacent tissue including the skin dorsally to the neuroma. This is to prevent pain caused by any microscopic spills of RTX during the. A second local anesthetic depot will be placed 1-2 cm proximally to the injection site around the affected branch of the plantar nerve to prevent pain caused by passive current transmission by axonal RTX excitation. Following the course of the affected nerve branch and ultra-sound visualization of the injection site, 0.5-2 ml bupivacaine 0.5% will be injected perineurally. Once the site has sufficient nerve block, the required RTX dose in a solution of 0.25 ml will be injected directly proximal to the Morton s neuroma under ultra-sound visualization.
Study: NCT05828069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-Positron Emission Tomography and Computed Tomography Scan
Description: Undergo FDG-PET imaging
Study: NCT06517914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH35995
Description: Oral administration of YH35995
Study: NCT05828069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tovorafenib
Description: Given PO
Study: NCT04576117

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT06517914

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of Placebo
Study: NCT05738434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib
Description: camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investigator' choice： paclitaxel 135\~150 mg/m2, i.v. d1,q3w; paclitaxel-albumin 150\~180 mg/m2, i.v. d1,q3w. up to 4 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w; apatinib 250 mg, p.o. qd,q3w
Study: NCT04576117

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selumetinib Sulfate
Description: Given PO
Study: NCT05738434

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab+Chemotherapy→Camrelizumab
Description: camrelizumab 200 mg, i.v. d1,q3w; cisplatin 25 mg/m2, i.v. d1-d3,q3w; According to investgator' choice： paclitaxel 175 mg/m2, i.v. d1,q3w; paclitaxel-albumin 200 mg/m2, i.v. d1,q3w up to 6 cycles and sequential maintenance therapy： camrelizumab 200 mg, i.v. d1,q3w;
Study: NCT05995262

Intervention type: OTHER
Intervention: Chart Review
Description: Data collection via retrospective chart review of patients from the Cedar Hill Clinic who had at least two visits with the clinical pharmacist between January 5, 2022 through December 31, 2022
Study: NCT04329221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol Only Product in Cutaneous Dose Form
Description: Calcipotriol (Calcipotriene) is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 5FU
Description: 5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical 5FU
Description: 5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
Study: NCT05357820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-106, Itraconazole
Description: single dose AB-106 at Day1, Itraconazole QD at Day14\~Day28, single dose AB-106 at Day17

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-106, Rifampicin
Description: single dose AB-106 at Day1, Itraconazole QD at Day14\~Day32, single dose AB-106 at Day21
Study: NCT06171711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure Therapy
Description: The proposed study will explore whether Exp-AN works via inhibitory learning (i.e., decreasing anxious beliefs and increasing anxiety tolerance) and/or between-session habituation (i.e., decreasing anxiety levels across therapy sessions), and the importance of targeting anxiety about eating versus weight gain. Results will provide information about the degree to which all three mechanisms of action (i.e., changes in anxiety ratings, anxious beliefs, and tolerance of anxiety) predict improved AN symptomatology across both treatments. Research that discovers whether specific treatments (e.g., Exp-AN) work in the way the investigators think they do (e.g., by increasing tolerance of anxiety), and whether modifying intervention targets (e.g., tolerance of anxiety) helps people get better (e.g., reduced AN symptomatology), will ultimately lead to more personalized, mechanism-based, and effective treatments (Insel 2014; Insel et al., 2010).
Study: NCT06337838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Injectable Solution
Description: Intravenous desmopressin, 20 mcg, single dose administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin Injectable Solution
Description: Intravenous desmopressin, 20 mcg, single dose administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Product
Description: Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.
Study: NCT05026996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen
Description: Single subcutaneous injection of pelacarsen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelacarsen
Description: Single subcutaneous injection of pelacarsen
Study: NCT04731246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-oculography / Neuropsychological evaluations
Description: Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET/CT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.
Study: NCT04576117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Sulfate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV
Study: NCT06548815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR4
Description: Ascending single doses - 4 dose levels.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ascending single doses - 4 dose levels.
Study: NCT06337838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Injectable Product
Description: Intravenous tranexamic acid, 1000 mg single dose administration for patients with eGFR\<25 not yet receiving dialysis OR 500 mg single dose administration for patients receiving dialysis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous 0.9% saline solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous 0.9% saline solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous 0.9% saline solution
Study: NCT06325696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hymecromone
Description: 400 mg
Study: NCT05713799

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: selective beta3-AR agonist approved

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mirabegron
Description: selective beta3-AR agonist approved

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-lipoic acid
Description: ALA is an antioxidant that is available over the counter
Study: NCT05663320

Intervention type: OTHER
Group type: OTHER
Intervention: virtual educational based transition intervention self-paced
Description: study intervention is a standardized, virtual educational video on CAH that will be delivered self-paced
Study: NCT06441487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Decision Support
Description: Subjects randomized to this arm receive a link to a mobile health decision support tool (mPATH™- Cloud). Within mPATH™-Cloud, subjects are invited to answer brief questions to confirm eligibility, view a video to help them identify their CRC screening preference, and request either colonoscopy or fecal immunochemical test (FIT) screening from their primary care provider. Subjects who select FIT, as well as subjects who do not click on the link or select a screening test receive a FIT mailed to their home address.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The study team will send subjects a prompt to visit the mobile health decision support tool (mPATH™-Cloud). Subjects with a mobile phone (as determined by their electronic health record) will receive a link to mPATH-Cloud by text. Subjects with a mailing address, but no mobile phone number in the EHR, will receive a letter inviting them to access mPATH-Cloud via URL code. Within mPATH-Cloud, subjects are invited to answer brief questions to confirm eligibility, view a video to help them identify their CRC screening preference, and request either colonoscopy or fecal immunochemical test (FIT) screening from their primary care provider. Subjects who do not click on the link or select a screening test receive a FIT.
Study: NCT06427928

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Explains the perioperative process with pictures
Description: We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Explains the perioperative process with pictures
Description: We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The perioperative process is only explained
Description: We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: The perioperative process is only explained
Description: We will draw pictures of the preoperative area, operating room and postoperative areas of our operating room and explain the process to 34 of the children who will undergo surgery with these pictures. We will explain the process to the other 34 people without the pictures we have. We planned to measure the anxiety levels between the two groups with the modified Yale scale.
Study: NCT04507178

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nadroparin Injectable Product
Description: high dose LMWH compared to prophylactic dose LMWH
Study: NCT05090683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body mobile application
Description: Self-directed; Study team will recommend daily use of mobile app for 6 weeks with a minimum of 4 times/week usage of mobile app for 6 weeks. Frequency will be monitored via weekly surveys.
Study: NCT05353439

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat Hydrobromide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study: NCT06455241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HABIT (Hand Activities Behavior Intervention)
Description: A Novel Occupational Therapy Intervention for Enhancing Daily Hand-Use of the affected upper extremity Among Individuals post Stroke.
Study: NCT06170619

Intervention type: DEVICE
Intervention: Obsidio™ Conformable Embolic
Description: Embolization with Obsidio™ Conformable Embolic.
Study: NCT05359445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA401 (Phase Ia)
Description: Intravenous infusions in escalating dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA401 (Phase Ia)
Description: Intravenous infusions in escalating dose levels

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (Phase Ia)
Description: Intravenous infusions in escalating dose levels for combination of IMA 401 and Pembrolizumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA 401 (Phase Ib)
Description: Treatment at recommended dose for extension (RDE)